<p>Prime Medicine（納斯達克代碼：PRME - 獲取免費報告）在週一發佈的報告中被 Wall Street Zen 的分析師從 “賣出” 評級下調至 “強烈賣出” 評級。</p>
<p>獲取 <strong>Prime Medicine</strong> 警報：</p>
<p>其他一些券商也對 PRME 發表了看法。Weiss Ratings 在 12 月 29 日的報告中重申了對 Prime Medicine 股票的 “賣出（d-）” 評級。Lifesci Capital 在 3 月 2 日的報告中將 Prime Medicine 的股票評級上調至 “強烈買入”。最後，Oppenheimer 在 3 月 12 日的報告中開始覆蓋 Prime Medicine 的股票。他們對該股票設定了 “跑贏大盤” 評級和 11.00 美元的目標價。一位分析師給予該股票 “強烈買入” 評級，四位分析師給予 “買入” 評級，三位分析師給予 “持有” 評級，一位分析師給予 “賣出” 評級。根據 MarketBeat.com 的數據，該股票的共識評級為 “適度買入”，平均目標價為 7.38 美元。</p>
<p><strong>查看我們關於 PRME 的最新研究報告</strong></p>
<h2>Prime Medicine 價格表現</h2>
<p>週一，PRME 的股票開盤價為 3.70 美元。該公司的市值為 6.6829 億美元，市盈率為-2.74，貝塔值為 2.65。公司的 50 日移動平均線為 3.69 美元，200 日移動平均線為 3.96 美元。Prime Medicine 的 52 周低點為 1.11 美元，52 周高點為 6.94 美元。</p>
<h2>對 Prime Medicine 的對沖基金看法</h2>
<p>幾家對沖基金和其他機構投資者最近對該公司的持倉進行了調整。Pictet Asset Management Holding SA 在第一季度以 42,000 美元的估值收購了 Prime Medicine 的股票。Rockefeller Capital Management L.P.在第四季度將其在 Prime Medicine 的持股提高了 10,557.7%。Rockefeller Capital Management L.P.目前擁有 121,391 股該公司的股票，估值為 421,000 美元，此前在上個季度又收購了 120,252 股。Caitong International Asset Management Co. Ltd 在第四季度以 134,000 美元的估值收購了 Prime Medicine 的股票。Chelsea Counsel Co.在第四季度將其在 Prime Medicine 的持股提高了 9.0%。Chelsea Counsel Co.目前擁有 227,000 股該公司的股票，估值為 788,000 美元，此前在上個季度又收購了 18,790 股。最後，Virtu Financial LLC 在第四季度將其在 Prime Medicine 的持股提高了 701.2%。Virtu Financial LLC 目前擁有 94,778 股該公司的股票，估值為 329,000 美元，此前在上個季度又收購了 82,948 股。機構投資者和對沖基金持有該公司 70.37% 的股票。</p>
<h2>Prime Medicine 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>我們是一家生物技術公司，致力於提供一種新型的差異化一次性治癒基因療法——Prime Editors，以通過部署我們的 Prime Editing 技術來解決最廣泛的疾病譜系。我們認為這是一種多功能、精確、高效且廣泛的基因編輯技術。與疾病相關的基因突變多種多樣，可能從單個鹼基的錯誤（稱為點突變）到超出單個鹼基的錯誤，如插入、缺失、重複或其組合。</p>
<h2>另請參見</h2>
<ul>
<li>我們更看好的五隻股票，而不是 Prime Medicine</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UFJNRQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UFJNRQ"/></p>
<p><em>此即時新聞警報由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Prime Medicine 嗎？</h2>
<p>在你考慮 Prime Medicine 之前，你需要聽聽這個。</p>
<p>MarketBeat 跟蹤華爾街頂級評級和表現最佳的研究分析師及其每日推薦的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前立即購買……而 Prime Medicine 並不在名單上。</p>
<p>雖然 Prime Medicine 目前在分析師中有 “適度買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

PRME

標普生物技術 3 倍做多 - Direxion

基因改革 ETF - ARK

標普生物技術 ETF - SPDR

IBBQ

生物科技 ETF - VanEck Vectors

2 倍做多納斯達克生物技術 ETF - ProShares

動態生物技術與基因組 ETF - Invesco

紐交所高增長板生物技術指數 ETF - First Trust

納斯達克生物科技指數 ETF - iShares Nasdaq

<p>華爾街禪將 Prime Medicine（NASDAQ:PRME）的評級從 “賣出” 下調至 “強烈賣出”。其他券商的意見不一，Weiss Ratings 維持 “賣出（d-）” 評級，而 Lifesci Capital 則上調至 “強力買入”。該股票的共識評級為 “適度買入”，平均目標價為 7.38 美元。PRME 開盤價為 3.70 美元，市值為 6.6829 億美元。機構投資者持有該股票的 70.37%，儘管評級下調，但仍反映出顯著的投資興趣</p>

<p>Prime Medicine (NASDAQ:PRME - Get Free Report) was downgraded by analysts at Wall Street Zen from a &#34;sell&#34; rating to a &#34;strong sell&#34; rating in a report issued on Monday.</p>
<div class="lb-trans"><p>Prime Medicine（納斯達克代碼：PRME - 獲取免費報告）在週一發佈的報告中被 Wall Street Zen 的分析師從 “賣出” 評級下調至 “強烈賣出” 評級。</p>
</div><p>Get <strong>Prime Medicine</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Prime Medicine</strong> 警報：</p>
</div><p>A number of other brokerages have also weighed in on PRME. Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Prime Medicine in a report on Monday, December 29th. Lifesci Capital upgraded shares of Prime Medicine to a &#34;strong-buy&#34; rating in a report on Monday, March 2nd. Finally, Oppenheimer assumed coverage on shares of Prime Medicine in a report on Thursday, March 12th. They set an &#34;outperform&#34; rating and a $11.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $7.38.</p>
<div class="lb-trans"><p>其他一些券商也對 PRME 發表了看法。Weiss Ratings 在 12 月 29 日的報告中重申了對 Prime Medicine 股票的 “賣出（d-）” 評級。Lifesci Capital 在 3 月 2 日的報告中將 Prime Medicine 的股票評級上調至 “強烈買入”。最後，Oppenheimer 在 3 月 12 日的報告中開始覆蓋 Prime Medicine 的股票。他們對該股票設定了 “跑贏大盤” 評級和 11.00 美元的目標價。一位分析師給予該股票 “強烈買入” 評級，四位分析師給予 “買入” 評級，三位分析師給予 “持有” 評級，一位分析師給予 “賣出” 評級。根據 MarketBeat.com 的數據，該股票的共識評級為 “適度買入”，平均目標價為 7.38 美元。</p>
</div><p><strong>Check Out Our Latest Research Report on PRME</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 PRME 的最新研究報告</strong></p>
</div><h2>Prime Medicine Price Performance</h2>
<div class="lb-trans"><h2>Prime Medicine 價格表現</h2>
</div><p>Shares of PRME opened at $3.70 on Monday. The firm has a market cap of $668.29 million, a PE ratio of -2.74 and a beta of 2.65. The company's fifty day moving average is $3.69 and its two-hundred day moving average is $3.96. Prime Medicine has a fifty-two week low of $1.11 and a fifty-two week high of $6.94.</p>
<div class="lb-trans"><p>週一，PRME 的股票開盤價為 3.70 美元。該公司的市值為 6.6829 億美元，市盈率為-2.74，貝塔值為 2.65。公司的 50 日移動平均線為 3.69 美元，200 日移動平均線為 3.96 美元。Prime Medicine 的 52 周低點為 1.11 美元，52 周高點為 6.94 美元。</p>
</div><h2>Hedge Funds Weigh In On Prime Medicine</h2>
<div class="lb-trans"><h2>對 Prime Medicine 的對沖基金看法</h2>
</div><p>Several hedge funds and other institutional investors have recently made changes to their positions in the business. Pictet Asset Management Holding SA acquired a new position in shares of Prime Medicine during the 1st quarter valued at $42,000. Rockefeller Capital Management L.P. lifted its holdings in shares of Prime Medicine by 10,557.7% during the 4th quarter. Rockefeller Capital Management L.P. now owns 121,391 shares of the company's stock valued at $421,000 after acquiring an additional 120,252 shares in the last quarter. Caitong International Asset Management Co. Ltd acquired a new position in shares of Prime Medicine during the 4th quarter valued at $134,000. Chelsea Counsel Co. lifted its holdings in shares of Prime Medicine by 9.0% during the 4th quarter. Chelsea Counsel Co. now owns 227,000 shares of the company's stock valued at $788,000 after acquiring an additional 18,790 shares in the last quarter. Finally, Virtu Financial LLC lifted its holdings in shares of Prime Medicine by 701.2% during the 4th quarter. Virtu Financial LLC now owns 94,778 shares of the company's stock valued at $329,000 after acquiring an additional 82,948 shares in the last quarter. Institutional investors and hedge funds own 70.37% of the company's stock.</p>
<div class="lb-trans"><p>幾家對沖基金和其他機構投資者最近對該公司的持倉進行了調整。Pictet Asset Management Holding SA 在第一季度以 42,000 美元的估值收購了 Prime Medicine 的股票。Rockefeller Capital Management L.P.在第四季度將其在 Prime Medicine 的持股提高了 10,557.7%。Rockefeller Capital Management L.P.目前擁有 121,391 股該公司的股票，估值為 421,000 美元，此前在上個季度又收購了 120,252 股。Caitong International Asset Management Co. Ltd 在第四季度以 134,000 美元的估值收購了 Prime Medicine 的股票。Chelsea Counsel Co.在第四季度將其在 Prime Medicine 的持股提高了 9.0%。Chelsea Counsel Co.目前擁有 227,000 股該公司的股票，估值為 788,000 美元，此前在上個季度又收購了 18,790 股。最後，Virtu Financial LLC 在第四季度將其在 Prime Medicine 的持股提高了 701.2%。Virtu Financial LLC 目前擁有 94,778 股該公司的股票，估值為 329,000 美元，此前在上個季度又收購了 82,948 股。機構投資者和對沖基金持有該公司 70.37% 的股票。</p>
</div><h2>Prime Medicine Company Profile</h2>
<div class="lb-trans"><h2>Prime Medicine 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>We are a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, Prime Editors, to address the widest spectrum of diseases by deploying our Prime Editing technology, which we believe is a versatile, precise, efficient and broad gene editing technology. Genetic mutations implicated in disease are diverse and can range from errors of a single base, known as point mutations, to errors that extend beyond a single base, such as insertions, deletions, duplications, or combinations thereof.</p>
<div class="lb-trans"><p>我們是一家生物技術公司，致力於提供一種新型的差異化一次性治癒基因療法——Prime Editors，以通過部署我們的 Prime Editing 技術來解決最廣泛的疾病譜系。我們認為這是一種多功能、精確、高效且廣泛的基因編輯技術。與疾病相關的基因突變多種多樣，可能從單個鹼基的錯誤（稱為點突變）到超出單個鹼基的錯誤，如插入、缺失、重複或其組合。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另請參見</h2>
</div><ul>
<li>Five stocks we like better than Prime Medicine</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，而不是 Prime Medicine</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UFJNRQ" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=PRME"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞警報由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Prime Medicine Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Prime Medicine 嗎？</h2>
</div><p>Before you consider Prime Medicine, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Prime Medicine 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prime Medicine wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 跟蹤華爾街頂級評級和表現最佳的研究分析師及其每日推薦的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前立即購買……而 Prime Medicine 並不在名單上。</p>
</div><p>While Prime Medicine currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Prime Medicine 目前在分析師中有 “適度買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Prime Medicine (NASDAQ:PRME) Stock Rating Lowered by Wall Street Zen

Market Beat

Prime Medicine

Invesco Nasdaq Biotechnology ETF

奧本海默控股

財通證券

Virtu Finc

Prime Medicine（納斯達克股票代碼：PRME）的股票評級被華爾街 Zen 下調